H.C. Wainwright analyst Edward White lowered the firm’s price target on Nyxoah (NYXH) to $15 from $17 and keeps a Buy rating on the shares after the company announced that the FDA has issued an Approvable Letter regarding the Pre-Market Approval application for the Genio system to treat moderate-to-severe obstructive sleep apnea. The firm now expect a U.S. commercial launch of Genio to be delayed by six months into early 2026 following the news, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NYXH: